A new study reveals nuanced findings on the neuropsychiatric risks of prenatal cannabis exposure. The research found a slight increase in the risk of ADHD and a heightened vulnerability to cannabis use in offspring. These results highlight the need for continued caution and further investigation into the long-term effects of cannabis use during pregnancy.
A new study led by Prof. Ilan Matok and Hely Bassalov PharmD from the Department of Clinical Pharmacy at the School of Pharmacy in the Faculty of Medicine at Hebrew University in collaboration with Prof. Omer Bonne and Dr. Noa Yakirevich-Amir from the Department of Psychiatry at the Hadassah Medical Center, sheds light on the potential long-term neuropsychiatric risks associated with prenatal cannabis exposure. As the global trend toward cannabis legalization continues, the prevalence of cannabis use among pregnant women is on the rise, raising concerns about its impact on fetal development.
The study, a comprehensive systematic review and meta-analysis involving over 500,000 participants from observational studies, aimed to assess the potential risks posed by prenatal exposure to Δ9-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis. THC is known to cross the placenta, potentially affecting the developing fetal brain.
The results of the study provide a nuanced understanding of the potential risks. Most notably, the findings indicate no significant association between prenatal cannabis exposure and an increased risk of autism spectrum disorder (ASD), psychotic symptoms, anxiety, or depression in offspring. However, the study did identify a slight increase in the risk of attention-deficit/hyperactivity disorder (ADHD) and a heightened vulnerability to cannabis consumption in children exposed to cannabis in utero.
“These findings suggest that while prenatal cannabis exposure does not appear to significantly increase the risk for many neuropsychiatric disorders, there is still a mild increase in the risk for ADHD and a greater likelihood of cannabis use in the offspring,” said Prof. Matok. “This calls for cautious interpretation, as it does not confirm the safety of cannabis consumption during pregnancy.”
The study emphasizes the importance of continued research in this area, especially given that most of the studies on the subject were conducted between the 1980s and early 2000s, when cannabis was characterized by considerably lower Δ9-THC content than currently used compounds. Thus, findings presented in the current study may potentially underestimate the impact of contemporary prenatal cannabis exposure on the long-term neuropsychiatric outcomes.
“While our study provides important insights, it is crucial to recognize that these results are not definitive. Pregnant women should be aware of the potential risks, and healthcare providers should continue to advise caution when it comes to cannabis use during pregnancy,” Prof. Matok added.
This research marks a significant step forward in understanding the complex relationship between prenatal cannabis exposure and neuropsychiatric outcomes in children. As the legal landscape surrounding cannabis continues to evolve, studies like this will be essential in guiding public health recommendations and ensuring the well-being of future generations.
Methodology: The methodology of this systematic review and meta-analysis involved analyzing 18 observational studies, with 17 included in the quantitative analysis, covering 534,445 participants. The review compared neuropsychiatric outcomes in offspring exposed to cannabis prenatally to those unexposed, focusing on conditions such as ADHD, ASD, anxiety, depression, psychotic disorders, and substance use.
The studies spanned from the 1980s to early 2000s, reflecting older cannabis potencies, and included data from multiple countries, with the literature search completed by January 2024.
The research paper titled “Prenatal cannabis exposure and the risk for neuropsychiatric anomalies in the offspring: a systematic review and meta-analysis” is now available at American Journal of Obstetrics and Gynecology and can be accessed at https://www.sciencedirect.com/science/article/pii/S0002937824006823?dgcid=author#sec4 .
Researchers:
Hely Bassalov Pharm1, Noa Yakirevich-Amir2, Inbal Reuveni3, Catherine Monk4,5, Sharon Florentin2, Omer Bonne2, Ilan Matok1
Institution:
- Department of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
- Department of Psychiatry, Hadassah Medical Center, Jerusalem, Israel
- Psychiatric Division, Sourasky Medical Center, Tel Aviv-Yafo, Israel
- Department of Obstetrics and Gynecology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY
- New York State Psychiatric Institute, New York, NY
The Hebrew University of Jerusalem is Israel’s premier academic and research institution. With over 23,000 students from 90 countries, it is a hub for advancing scientific knowledge and holds a significant role in Israel’s civilian scientific research output, accounting for nearly 40% of it and has registered over 11,000 patents. The university’s faculty and alumni have earned eight Nobel Prizes, two Turing Awards a Fields Medal, underscoring their contributions to ground-breaking discoveries. In the global arena, the Hebrew University ranks 81st according to the Shanghai Ranking. To learn more about the university’s academic programs, research initiatives, and achievements, visit the official website at http://new.huji.ac.il/en
